Pregnant patients with T2IDs using dupilumab did not have an increased rate of adverse events when compared with patients not receiving dupilumab.

Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

2 Trap Falls Road Suite 106, Shelton, CT 06484 USA Ph: +1-203-852-6800, 800-243-6002 ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older.

Saudi Society of Dermatology and Sanofi Sign MoU to Advance Dermatological Care in Saudi Arabia ...